Showing results (1-10 of 346) with videos related to
Sort By:
Pageof 35
Nature Reviews. Clinical Oncology|April 5, 2012
Treating ALK-positive lung cancer--early successes and future challengesD Ross Camidge, Robert C DoebeleNature Reviews. Clinical Oncology|February 6, 2019
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLCD Ross Camidge, Robert C Doebele, Keith M KerrFrontiers in Oncology|April 16, 2019
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung CancerJose M Pacheco, D Ross Camidge, Robert C Doebele, et al.Lung Cancer (Amsterdam, Netherlands)|January 23, 2010
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancerRobert C Doebele, Ana B Oton, Nir Peled, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 11, 2020
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLCThomas E Stinchcombe, Robert C Doebele, Xiaofei Wang, et al.Cancer|January 3, 2013
Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancerAndrew J Weickhardt, Dara L Aisner, Wilbur A Franklin, et al.Clinical Lung Cancer|September 22, 2024
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung CancerKyle F Concannon, Bonnie S Glisson, Robert C Doebele, et al.International Journal of Radiation Oncology, Biology, Physics|January 28, 2014
Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinibGregory N Gan, Andrew J Weickhardt, Benjamin Scheier, et al.Clinical Lung Cancer|September 11, 2018
First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic SignificanceWade T Iams, Hui Yu, Yu Shyr, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2016
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung CancerRafal Dziadziuszko, Anh T Le, Anna Wrona, et al.Pageof 35